Creating targeted drugs to fight severe Pseudomonas infections
Development of Targeted Antipseudomonal Bactericidal Prodrugs
['FUNDING_R01'] · CORNELL UNIVERSITY · NIH-11011255
This study is looking at new medicines that can safely and effectively fight a tough bacteria called Pseudomonas aeruginosa, which can cause serious infections, especially in people with weakened immune systems.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CORNELL UNIVERSITY (nih funded) |
| Locations | 1 site (ITHACA, UNITED STATES) |
| Trial ID | NIH-11011255 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new drugs that specifically target and kill Pseudomonas aeruginosa, a bacteria responsible for serious bloodstream infections. The approach involves creating prodrugs that release their active antimicrobial components only when they reach the infection site, minimizing side effects. By using targeted antibody conjugates, the research aims to enhance the effectiveness of treatment while reducing toxicity, especially for patients with compromised immune systems. The study will explore the use of synthetic antimicrobial peptides that can overcome existing antibiotic resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with bloodstream infections caused by Pseudomonas aeruginosa, particularly those with weakened immune systems or undergoing chemotherapy.
Not a fit: Patients with infections caused by bacteria other than Pseudomonas aeruginosa may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from life-threatening infections caused by antibiotic-resistant bacteria.
How similar studies have performed: Previous research has shown promise in using targeted antimicrobial peptides, but this specific approach of creating targeted antibody conjugate prodrugs is relatively novel.
Where this research is happening
ITHACA, UNITED STATES
- CORNELL UNIVERSITY — ITHACA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ALABI, CHRISTOPHER AKINLEYE — CORNELL UNIVERSITY
- Study coordinator: ALABI, CHRISTOPHER AKINLEYE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Airway infections, anti-cancer therapy, anti-microbial resistant infection